AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TNXP · NASDAQ · Biotechnology

Tonix Pharmaceuticals

Commercializes TONMYA for fibromyalgia alongside branded acute migraine treatments.

$13.59

After-hours close+0.02 (+0.15%)

At close$13.57(+0.07%)

Something off on this page? Send us feedback.

Profile

Tonix Pharmaceuticals Holding Corp.TNXPHealth Care

Markets TONMYA for fibromyalgia and branded acute migraine treatments, with sales concentrated in the United States. The business is shifting from development to commercialization while carrying CNS, infectious-disease, immunology, and rare-disease programs.

Markets TONMYA, an FDA-approved treatment for fibromyalgia in adults, alongside Zembrace SymTouch and Tosymra for acute migraine. Sales are concentrated in the United States, and the company reports through one operating segment.

Built around a long sublingual cyclobenzaprine development arc, the business now pairs commercial execution with a broad research agenda. Its platform includes sales, marketing, market access, distribution, patient support, and research programs across CNS, infectious disease, immunology, and rare disease.

Operating posture depends on TONMYA adoption and payer access after launch, continuing regulatory obligations for approved medicines, and progress across investigational programs outside the current marketed portfolio.

Company facts

CEOSeth Lederman, MD

ListedAug 9, 2013

ExchangeNASDAQ

HeadquartersBerkeley Heights, NJ

CountryUnited States

Employees142

CIK0001430306

ISINUS8902608392

Key statistics

Market cap$216.6M

EPS (ttm)−$13.24

P/E (ttm)−1.03

ROE-69.0%

P/B1.02

P/S7.44

Dividend yield—

Beta2.18vs XLV 0.37

Year to date −18.0% · Average volume (30d) 491.4K

Analysts

Price target, next 12 months$27.00+98.7%Median of 7 analysts · vs the Aug 28 close

ConsensusBuy6 of 7 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $13.59

High$27.00+98.7%

Median$27.00+98.7%

Low$27.00+98.7%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 10, 2026	Raymond James	Reiterate	Strong Buy	$26	$27
Jun 24, 2026	Raymond James	Initiate	Strong Buy		$26

Earnings

EPS

Estimate−$2.43

ReportedDue Nov 9, 2026

Revenue

Estimate$16.2M

ReportedDue Nov 9, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 10, 2026Q2 FY26	−$2.64	−$2.44	+7.6%	$7.7M	$13.5M	+75.4%	+4.66%
May 11, 2026Q1 FY26	−$2.54	−$2.93	−15.4%	$6.1M	$6.9M	+12.3%	−5.88%
Mar 12, 2026Q4 FY25	−$3.16	−$3.98	−25.9%	$3.0M	$5.4M	+81.7%	−1.27%
Nov 10, 2025Q3 FY25	−$3.59	−$3.59	0.0%	$3.0M	$3.3M	+10.9%	+4.10%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$2.4M	$2.0M	$3.3M	$5.4M	$6.9M	$13.5M
Gross profit	$1.5M	−$1.3M	$1.9M	$3.8M	$4.7M	$12.8M
Operating income	−$16.1M	−$28.3M	−$33.1M	−$48.3M	−$41.5M	−$42.5M
Net income	−$16.8M	−$28.3M	−$32.0M	−$46.9M	−$40.2M	−$40.6M
Diluted EPS	−$2.84	−$3.86	−$3.59	−$4.28	−$2.93	−$2.44
Gross margin	61.2%	-63.8%	58.4%	71.3%	69.0%	94.8%
Operating margin	-660.9%	-1,416.2%	-1,005.1%	-895.8%	-603.9%	-314.1%

Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $7.8M · FY24 $10.1M · FY25 $13.1M

Balance sheet, Jun 30, 2026Cash & short-term investments $176.2M · Total debt $1.3M · Total assets $254.1M · Shareholders' equity $222.3M

Dividends

No dividends on record.

Ownership

Institutions 59.08%9.42M sharesInsiders 0.25%39.2K sharesOther 40.67%6.48M shares

Shares outstanding 15.94M · Float 15.89M · 99.7% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	1.40M	8.77%	13F	Aug 7, 2026
Sirenia Capital Management LP	1.30M	8.80%	13G	May 15, 2026
Point72 Asset Management, L.P.	1.17M	7.32%	13F	Aug 14, 2026
Millennium Management LLC	966.9K	6.07%	13F	Aug 14, 2026
AQR Capital Management LLC	882.6K	5.54%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 20, 2026	Richard H. Bagger	director	+1,000	$12.60
Jun 12, 2026	Carolyn E. Taylor	director	+1,415	$10.55
Jun 9, 2026	Seth Lederman	director, officer: Chief Executive Officer	+5,000	$11.79
Jun 8, 2026	Richard Newcomb Stillwell	director	+5,000	$11.65
Mar 31, 2026	Seth Lederman	director, officer: Chief Executive Officer	+5,000	$12.62